Pharmaceutical care for a patient with subacute stent thrombosis complicated with liver-function abnormalities after PCI

HUANG Ying; SUN Li; FAN Rui

doi:10.3969/j.issn.1006-0111.2019.02.017

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To participate in the clinical treatment and pharmaceutical care for a patient with subacute stent thrombosis complicated with liver-function abnormalities after percutaneous coronary intervention(PCI)and to explore the role of clinical pharmacists in the treatment group. Methods Clinical pharmacists took an active part in the treatment process by analyzing the causes of subacute stent thrombosis and abnormal liver function after PCI.Pharmaceutical professional knowledge was used according to the patient's condition,genotype,combined medication,interaction,and adverse reaction and so on.The patient's antiplatelet therapy was timely adjusted to ticagrelor 90 mg po bid,and the dose of rosuvastatin was 10 mg po qn.Pharmaceutical care and medication education were also provided. Results The suggestions of clinical pharmacists were adopted by physicians and the patient was recovered. Conclusion Clinical pharmacists should use professional skill to assist physician to adjust the drug treatment program for patients,so as to guarantee the safe and effective of medicines use.

Pharmaceutical care for a patient with subacute stent thrombosis complicated with liver-function abnormalities after PCI

1. Department of pharmacy, the Second Division of XinJiang Korla Hospital, Korla XinJiang 841000, Chian

2. Department of pharmacy, The people's Hospital of the Autonomous Region, Institute of clinical pharmacy, Urumqi XinJiang 830000, China

3. Department of pharmacy, the Ninth Division of XinJiang Hospital, TaCheng XinJiang 834601, China

Received Date: 2018-05-11

Rev Recd Date: 2018-12-26

Key words:

Abstract: Objective To participate in the clinical treatment and pharmaceutical care for a patient with subacute stent thrombosis complicated with liver-function abnormalities after percutaneous coronary intervention(PCI)and to explore the role of clinical pharmacists in the treatment group. Methods Clinical pharmacists took an active part in the treatment process by analyzing the causes of subacute stent thrombosis and abnormal liver function after PCI.Pharmaceutical professional knowledge was used according to the patient's condition,genotype,combined medication,interaction,and adverse reaction and so on.The patient's antiplatelet therapy was timely adjusted to ticagrelor 90 mg po bid,and the dose of rosuvastatin was 10 mg po qn.Pharmaceutical care and medication education were also provided. Results The suggestions of clinical pharmacists were adopted by physicians and the patient was recovered. Conclusion Clinical pharmacists should use professional skill to assist physician to adjust the drug treatment program for patients,so as to guarantee the safe and effective of medicines use.

HTML

Reference (17)

[1]	D'ASCENZO F,BOLLATI M,CLEMENTI F,et al.Incidence and predictors of coronary stent thrombosis:evidence from an international collaborative meta-analysis including 30 studies,221,066 patients,and 4276 thromboses[J].Int J Cardiol,2013,167(2):575-584.
[2]	王彬,薛玉生,倪四峰,等.CYP2C19基因多态性与氯吡格雷药效的相关性研究[J].西北国防医学杂志,2016,37(8):531-534.
[3]	SIBBING D,STEGHERR J,LATZ W,et al.Cytochrome P4502C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention[J].Eur Heart J,2009,30(8):916-922.
[4]	吴伟明,黄成珂,王军,等.质子泵抑制剂对PCI术后患者服用氯吡格雷疗效影响的Meta分析[J].中国新药与临床杂志,2013,32(1):17-21.
[5]	冯美蓉,姜葵,吕宗舜,等.氯吡格雷联用质子泵抑制剂对心血管事件影响的Meta分析[J].临床荟萃,2012,27(2):108-113.
[6]	刘俊,朱艳虹,汪琳,等.临床药师参与1例经皮冠状动脉介入术后支架内血栓形成的个体化抗血小板治疗[J].中国医院药学杂志,2014,34(10):852-855.
[7]	PAN Y,TAN Y,LI B,et al.Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention:a Meta-analysis of fourteen randomized controlled trials[J].Lipids Health Dis,2015,14(8):97-105.
[8]	张兰芳,齐晓勇,贾新未,等.不同剂量瑞舒伐他汀对急性心肌梗死经皮冠状动脉介入治疗患者心肌再灌注及心功能的影响[J].中国临床药理学杂志,2015,31(13):1223-1226.
[9]	李宏松,许向东,吴国林,等.PCI术前应用负荷剂量瑞舒伐他汀对急性NSTEMI患者再灌注心律失常的影响[J].中国药房,2017,28(36):5064-5067.
[10]	NACI H,BRUGTS J,ADES T.Comparative tolerability and harms of individual statins:a study-level network meta-analysis of 246955 participants from 135 randomized,controlled trials[J].Circ Cardiovasc Qual Outcomes,2013,6(4):390-399.
[11]	ALSHEIKH-ALI A A,AMBROSE M S,KUVIN J T,et al.The safety of rosuvastatin as used in common clinical practice:a postmarketing analysis[J].Circulation,2005,111(23):3051-3057.
[12]	FAMULARO G,MIELE L,MINISOLA G,et al.Liver toxicity of rosuvastatin therapy[J].World J Gastroenterol,2007,13(8):1286-1288.
[13]	HARRILL A H,ROACH J,FIER I,et al.The effects of heparins on the liver:application of mechanistic serum biomarkers in a randomized study in healthy volunteers[J].Clin Pharmacol Ther,2012,92(2):214-220.
[14]	杨旭,黄晓青,张云,等.低分子量肝素与他汀类药物合用致转氨酶升高32例分析[J].中国循环杂志,2015,30(6):567-569.
[15]	RAMOS RAMOS J C,SANZ MORENO J,CALVO CARRASCO L,et al.Clopidogrel-induced hepatotoxicity[J].Med Clin (Barc),2003,120(4):156-157.
[16]	郑耐心,刘蔚,许乐.美托洛尔致氨基转移酶升高[J].药物不良反应杂志,2007,9(1):42.
[17]	马长辉,杨万松.血清丙氨酸转氨酶与ST段抬高型心肌梗死的相关性研究[J].天津医科大学学报,2014,20(2):116-119.

Message Board

Pharmaceutical care for a patient with subacute stent thrombosis complicated with liver-function abnormalities after PCI

doi: 10.3969/j.issn.1006-0111.2019.02.017

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views